ENvue Medical's UroShield Kit Added to NHS Drug Tariff, Enabling Nationwide Reimbursement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Source: Globenewswire
- Significant Milestone: ENvue Medical's UroShield® Kit has been included in the UK NHS Drug Tariff Part IX, establishing a nationwide prescription reimbursement pathway that significantly enhances market access and product availability across the UK.
- Initial Order Confirmation: The company has secured an initial purchase order from Peak Medical, a leading UK distributor, reflecting early commercial demand following the NHS Drug Tariff inclusion, which is expected to provide substantial revenue visibility heading into 2026.
- Infection Risk Reduction: The UroShield® device reduces the occurrence of catheter-associated urinary tract infections (CAUTIs) by applying low-frequency ultrasonic energy, addressing the approximately 6-7% catheter prevalence in long-term care populations and enhancing patient safety with a non-invasive solution.
- Market Expansion Potential: The inclusion in the Drug Tariff removes a major reimbursement barrier, enabling ENvue Medical to establish a presence in European markets, with plans to assess reimbursement frameworks in other countries to support expansion among large catheterized patient populations.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like FEED with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on FEED
About FEED
ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Meta Platforms Reports Strong Q4 Earnings, Shares Surge
- Strong Financial Results: Meta reported fourth-quarter revenue of $59.89 billion, exceeding analyst expectations of $58.30 billion, indicating robust performance in the recovering advertising market, which is likely to drive further stock price increases.
- Earnings Growth: The company posted adjusted earnings of $8.88 per share, surpassing the forecast of $8.16 per share, reflecting significant improvements in cost control and operational efficiency, thereby boosting investor confidence.
- Stock Price Surge: Following the earnings report, Meta's shares jumped 8.2% in pre-market trading to $723.70, indicating a positive market sentiment towards the company's growth prospects, which may attract more investor interest.
- Optimistic Sales Guidance: Meta's first-quarter sales guidance exceeded market expectations, further solidifying its leadership position in the digital advertising space and suggesting continued benefits from the recovery in advertising spending.
Continue Reading
ENvue Partners with U-Deliver for Nationwide Syringe Distribution
- Stock Surge: ENvue Medical, Inc. (FEED) shares soared 138% on Wednesday following the announcement of a distribution agreement with U-Deliver, indicating strong market enthusiasm for its new product line.
- Product Launch: The recently launched ENFit syringe line is designed to meet clinical needs for both feeding and medication delivery without requiring a prescription, enhancing its competitive edge in the market.
- Distribution Channel Expansion: The new agreement will leverage U-Deliver's digital and wholesale channels to broaden access to the ENFit syringes, which is expected to significantly increase market penetration.
- Market Sentiment Shift: On Stocktwits, retail sentiment around FEED shifted from 'bearish' to 'extremely bullish', with message volume rising from 'low' to 'extremely high', reflecting investor optimism about the company's future prospects.
Continue Reading